MSB 2.91% $1.06 mesoblast limited

Ann: Update on BLA for Graft Versus Host Disease, page-249

  1. 11,429 Posts.
    lightbulb Created with Sketch. 725
    With 7-80% of patients dying within 2-3 months the trial once started may finish quickly due to 'everwhelming efficacy' if that stat is improved significantly.

    People may get a surprise on the timeline accordingly.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.